General Methods
SPPS was carried out manually in syringes, equipped with teflon filters, purchased from Torviq or by using an automated peptide synthesizer (CS336X, CSBIO).
Analytical grade DMF was purchased from Biotech. Resins were purchased from Creosalus, protected amino acids were purchased from GL Biochem and activating reagents [(2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate Analytical HPLC was performed on a Thermo instrument (Dionex Ultimate 3000) using analytical columns Xbridge (waters, BEH300 C4, 3.5µm, 4.6 × 150 mm) and XSelect (waters, CSH C18, 3.5 µm, 4.6 × 150 mm) at flow rate of 1.2 mL/min. Semi preparative HPLC was performed on a Thermo Scientific instrument (Spectra System SCM1000) using Jupiter C4 10 µm, 300 Å, 250 × 10 mm column at flow rate 4 mL/min. Preparative HPLC was performed on a Waters instrument using XSelect C18 10µm 19 × 250 mm at flow rate of 25 mL/min. Synthetic products were purified by HPLC and characterized by mass spectrometry using LCQ Fleet Ion Trap (Thermo Scientific). For all HPLC based purifications water with 0.1% trifluoroacetic acid was used as a solvent A and acetonitrile with 0.1% trifluoroacetic acid as solvent B. All calculated masses have been reported as an average isotope composition. 1 H and 13 C-NMR spectra were recorded on a Bruker AMX-400 MHz using CD 3 OD as a solvent. Chemical shifts (δ) were reported in ppm and J values are given in Hz.
Mass determination of the materials was carried out using an LCQ Fleet Ion Trap (Thermo Scientific 
Synthesis of compound 19
The Fmoc-Cys-OMe 17 was dissolved in DMF (12 mL). 
Synthesis of peptides
All peptides were synthesized using standard SPPS protocol. The coupling agents were used in 4-fold and DIEA in 8-fold excess to the initial loading of the resin. For deprotection steps treatment with 20% piperidine in DMF was applied.
Cleavage from the resin: The resin was washed with DMF, MeOH, DCM and dried.
The peptide was cleaved with mixture of TFA:triisopropylsilane (TIS):water (95:2.5:2.5) for 2h at RT. The resin was removed by filtration and then washed again with the cleavage mixture. The combined filtrate was precipitated by drop-wise addition to 10-fold volume of cold ether. Then ether was decanted followed by dissolution of the peptide in acetonitrile-water. The HPLC analysis was carried out on a C18 analytical column using a gradient of 0-60% B over 40 min. For preparative HPLC, the same gradient was used to purify the desired product.
Synthesis of ubiquitin (1-70)-MMP 7
The synthesis was carried out on Knorr resin (0.27 mmol/g, 0.1 mmol scale) using automatic peptide synthesizer. 
Isolation of α-globin from hemoglobin sample
Commercially available (Sigma) lyophilized sample of human hemoglobin 30 mg was dissolved in 6M Gn·HCl buffer (1 mL, pH ~ 6) containing TCEP (7 mg). Purification was carried out using preparative HPLC using C4 column with the gradient 30-70% B over 50 min to obtain the desired α-globin (~ 9 mg). 
Synthesis of ubiquitin-Dha 9 and α-globin-Dha
Ubiquitin (10 mg), carrying Cys at defined position was dissolved in 450 µl 6M
Gn·HCl buffer pH 8. A solution of α, α"-di-bromo-adipyl(bis)amide reagent 2 was prepared by dissolving 37.9 mg (100 eq) in 150 µl DMF. This was added to ubiquitin solution and the reaction was continued for 30 min at room temperature, followed by 2.5 h at 37 ºC. The reaction was followed by analytical HPLC using C18 analytical column and gradient of 5-50% B over 40 min. For preparative HPLC, the same gradient was used to purify the desired product in 45% yield (4.5 mg) 
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A similar procedure was followed for the preparation of α-globin-Dha. 
Synthesis of hexapeptide-thiol 4
The synthesis was carried out manually in syringes, equipped with teflon filters, purchased from Torviq using Fmoc-SPPS on Rink amide resin (0.43 mmol/g, 0.4 mmol scale). Fmoc-Dbz was coupled to the resin, as described above, followed by SPPS to complete the sequence. The N-terminal Cys carries thiazolidine (Thz)
protecting group. The Dbz cyclization was performed on the peptide, followed by cleavage and lyophilization. The peptide was purified using C18 column on preparative HPLC with a gradient of 0-40% B over 60 min. Next, the purified hexapeptide-Nbz (10 mg, 50 mM) was dissolved in 6M Gn·HCl buffer pH 7 in the presence of 69 mg (50 eq) cysteamine and incubated for 30 minutes at RT. The desired hexapeptide-thiol 4 was purified using preparative HPLC with a gradient of 0-40% B over 60 min to give the desired product in 62% isolated yield (5.5 mg). 
Conjugation of hexapeptide-thiol 4 to ubiquitin-Dha 9
Under denaturating conditions: Ubiquitin-Dha 9 (4 mg, 2mM) was dissolved in 240 µl Gn·HCl buffer pH 8. To this solution, 14 mg hexapeptide-thiol 4 (40 eq.) was added and the reaction was incubated for 8 h at 37 ºC. The reaction was followed by analytical HPLC with C18 column and a gradient of 5-50B over 40 minutes.
Subsequently, 1.9 mg (50 eq.) of methoxylamine and 3.3 mg (25 eq.) of TCEP were added to this solution and incubated for additional 12 h at 37 ºC to unmask the Thz protection. Finally, the conjugated product was purified by HPLC using gradient of 5-50B over 40 minutes to give the desired product in ~57% isolated yield. Similarly, conjugation of hexapeptide-thiol 4 to α-globin-Dha (10 mg) was carried out to afford hexapeptide conjugated α-globin in ~50% yield (5.2 mg). 
Circular dichroism spectroscopy
The Ubiquitin-Dha was first dissolved in 6M urea solution (5% of the total volume) and then diluted with 20 mM Tris buffer, containing 150 mM NaCl, pH 7.3. With this solution circular dichroism spectrum was recorded in a Chirascan (Applied Photophysics) instrument.
Figure S12: CD spectra of folded ubiquitin48-Dha.
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11. Preparation of di-ubiquitin analogues.
Preparation of cysteine containing analogue 11
Ubiquitin-hexapeptide 10 (1 mg) and of ubiquitin(1-70)-MMP 7 (1.13 mg) were dissolved in 54 µl 6M Gn·HCl buffer pH ~7. To this solution 0.91 mg (50 eq.) of 4-mercaptophenylacetic acid (MPAA) and 0.78 mg (25 eq.) of tris(2-carboxyethyl)phosphine hydrochloride (TCEP) were added. The reaction was incubated for ~ 9 h at 37 ºC. The ligation was monitored by analytical HPLC followed by isolation in semipreparative HPLC using C4 column and a gradient of 5-50B over 40 minutes, affording 11 in 39% of isolated yield (0.72 mg). 
Preparation of desulfurized analogue 12
The previous ligation reaction mixture was dialyzed in a Slide-A-Lyzer 3.5K dialysis cassette (Thermo scientific, 0.1-0.5 mL) in 6M Gn·HCl, 200 mM phosphate buffer (500 mL) for overnight and then radical induced desulfurization was applied. 3 To the reaction mixture TCEP (~17 mg, 250 mmol), VA-044 (0.95 mg, 50 eqiv) and tertbutyl thiol (25 μl) were added and incubated at 37 °C for 6 h. The desired product was isolated using semipreparative HPLC with C4 column and a gradient of 5-50B over 40 minutes, affording analogue 12 in 35% isolated yield (0.35 mg). 
Preparation of alkylated analogue 13
Di-ubiquitin 11 (~0.7 mg, 4×10 -5 mmol) was dissolved in 10 µl 6M Gn·HCl 200 mM phosphate buffer (pH 7.5) and diluted with 90 µl of 50 mM Tris buffer (pH 7.5) containing 0.1 mM EDTA. Solution of the iodoacetamide was prepared by dissolving 0.4 mg (~50 eq) in 20 µl of 50% acetonitrile/water and added to the di-ubiquitin reaction mixture, followed by incubation for 1 h at 37 °C. The desired product was isolated using semipreparative HPLC and C4 column, 5-50% B over 40 min. 
Synthesis of wild type di-ubiquitin
Lys48 linked di-ubiquitin was synthesized as previously reported. 4
Enzymatic studies with USP2
The di-ubiquitin analogues were dissolved in 6M Gn·HCl 200 mM phosphate buffer (pH 7.5) and diluted 95% (v/v) with 50 mM Tris buffer (pH 7.5) containing 0.1mM EDTA. The exact final concentration of each protein solution was determined using Pierce® BCA Protein Assay Kit (Thermo scientific) and diluted to a final concentration of 6.66 µM. A stock solution of the USP2 (human catalytic domain, obtained form BostonBiochem, 2 µM) was prepared by diluting 50 µg of the enzyme in 50 mM Tris buffer (pH 7.54) containing 0.1 mM EDTA and 5 mM DTT. The enzymatic assay was initiated by incubating 5 µM solution of each substrate with USP2 (100 nM) for 30 min at 37 ºC. The cleavage pattern was monitored by SDS-PAGE.
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Figure S17: SDS-PAGE of the hydrolysis reaction of the prepared Lys48-linked diubiquitin analogues 11-13 by USP2 compared to the wild type reaction. Lines a and b correspond to WT di-ubiquitin with and without USP2, respectively. Lines c and d correspond to di-ubiquitin 12 with and without USP2, respectively. Lines e and f correspond to di-ubiquitin 11 with and without USP2, respectively. Lines g and h correspond to di-ubiquitin 13 with and without USP2, respectively.
Trypsin digestion of conjugated products 10
The conjugate 10 (~0.1 mg, 1.1×10 -5 mmol) was dissolved in 15 µl of 6M Gn·HCl 200 mM phosphate buffer (pH 7.7) and then diluted with 83 µl of 50 mM Tris buffer (pH 7.7), containing 150 mM NaCl. To this solution 2 µl (2 mg) of trypsin stock from porcine pancreas was added and the reaction was incubated for overnight at 37 °C.
Finally, trypsinized solution was analyzed with analytical HPLC using C18 column with gradient 0-40B over 40 minutes. α-globin-hexapeptide was also trypsinized using the same protocol. 
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